J2P-MC-LXBD: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506127-29-00

Acronym

J2P-MC-LXBD

Enrollment

146

Registered

2024-02-19

Start date

2024-03-05

Completion date

2025-06-11

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Brief summary

Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS)

Interventions

DRUGPlacebo to match LY3556050

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS)	—

Countries

Czechia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026